DeepMed Research

Amgen, Inc.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1980-01-01

Employees: 26.7K

Market Cap: $175.6B

Website: http://www.amgen.com

Clinical Trials

Study to Evaluate the Drug-drug Interaction Effect of Omeprazole on the Pharmacokinetics (PK) of AMG 510 in Healthy Participants

Phase 1

Completed

Conditions: Healthy Participants

Interventions: Drug: AMG 510
Drug: Omeprazole

First Posted Date: 2022-10-17

Last Posted Date: 2025-03-18

Lead Sponsor: Amgen

Target Recruit Count: 14

Registration Number: NCT05581992

Locations: 🇺🇸
Covance Clinical Research Unit, Inc, Daytona Beach, Florida, United States

Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction (OCEAN(a)) - Outcomes Trial

Phase 3

Active, not recruiting

Conditions: Atherosclerotic Cardiovascular Disease

Interventions: Drug: Placebo
Drug: Olpasiran

First Posted Date: 2022-10-14

Last Posted Date: 2024-11-12

Lead Sponsor: Amgen

Target Recruit Count: 7297

Registration Number: NCT05581303

Locations: 🇧🇷
Hospital Santa Izabel, Salvador, Bahia, Brazil
🇨🇿
Institut klinicke a experimentalni mediciny, Praha 4, Czechia
🇨🇿
Milan Kvapil sro, Praha 4, Czechia

and more 725 locations

A Study of the Absorption, Metabolism, and Excretion of [14C]-AMG 510 Following a Single Oral Dose in Healthy Male Subjects

Phase 1

Completed

Conditions: Healthy Subjects

Interventions: Drug: AMG 510

First Posted Date: 2022-10-13

Last Posted Date: 2022-11-07

Lead Sponsor: Amgen

Target Recruit Count: 8

Registration Number: NCT05578859

Locations: 🇺🇸
Covance Clinical Research Unit, Inc, Madison, Wisconsin, United States

A Study to Evaluate the Drug-drug Interaction Effect of Rifampin on the Pharmacokinetics of AMG 510 in Healthy Participants

Phase 1

Completed

Conditions: Healthy Participants

Interventions: Drug: AMG 510
Drug: Rifampin

First Posted Date: 2022-10-13

Last Posted Date: 2025-03-18

Lead Sponsor: Amgen

Target Recruit Count: 14

Registration Number: NCT05577624

Locations: 🇺🇸
Covance Clinical Research Unit, Inc 3402 Kinsman Boulevard, Madison, Wisconsin, United States

A Study to Evaluate the Relative Bioavailability of AMG 510 Administered as Tablets and as a Water Dispersion in Healthy Participants

Phase 1

Completed

Conditions: Healthy Participants

Interventions: Drug: AMG 510

First Posted Date: 2022-10-07

Last Posted Date: 2022-10-07

Lead Sponsor: Amgen

Target Recruit Count: 13

Registration Number: NCT05571163

Locations: 🇺🇸
Covance Clinical Research Unit, Inc 1341 W Mockingbird Ln, Ste 200E, Dallas, Texas, United States

A Study to Evaluate the Drug-drug Interaction Effect of Itraconazole on the Pharmacokinetics (PK) of AMG 510 in Healthy Participants

Phase 1

Completed

Conditions: Healthy Participants

Interventions: Drug: AMG 510
Drug: Itraconazole

First Posted Date: 2022-10-05

Last Posted Date: 2025-03-05

Lead Sponsor: Amgen

Target Recruit Count: 14

Registration Number: NCT05568082

Locations: 🇺🇸
Covance Clinical Research Unit, Inc, Daytona Beach, Florida, United States

A Study to Assess the Efficacy and Safety of Apremilast in Japanese Pediatric Participants With Moderate to Severe Plaque Psoriasis

Phase 3

Recruiting

Conditions: Plaque Psoriasis

Interventions: Drug: Apremilast

First Posted Date: 2022-10-04

Last Posted Date: 2025-02-06

Lead Sponsor: Amgen

Target Recruit Count: 33

Registration Number: NCT05565560

Locations: 🇯🇵
Nagoya City University Hospital, Nagoya-shi, Aichi, Japan
🇯🇵
Fukuoka University Hospital, Fukuoka-shi, Fukuoka, Japan
🇯🇵
Hospital of the University of Occupational and Environmental Health Japan, Kitakyushu-shi, Fukuoka, Japan

and more 26 locations

Study to Evaluate the Drug-drug Interactions Between Metformin and AMG 510 in Healthy Participants

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: AMG 510
Drug: Metformin

First Posted Date: 2022-09-22

Last Posted Date: 2025-03-05

Lead Sponsor: Amgen

Target Recruit Count: 13

Registration Number: NCT05550129

Locations: 🇺🇸
Covance Clinical Research Unit, Madison, Wisconsin, United States

Study of Inebilizumab in Pediatric Subjects With Neuromyelitis Optica Spectrum Disorder

Phase 2

Recruiting

Conditions: Neuromyelitis Optica Spectrum Disorder

Interventions: Drug: Inebilizumab

First Posted Date: 2022-09-22

Last Posted Date: 2025-01-09

Lead Sponsor: Amgen

Target Recruit Count: 15

Registration Number: NCT05549258

Locations: 🇬🇧
Great Ormond Street Hospital, London, London, City Of, United Kingdom
🇺🇸
Loma Linda University Children's Hospital, Loma Linda, California, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

and more 14 locations

Study of Daxdilimab (HZN-7734) in Participants With Active Proliferative Lupus Nephritis (LN)

Phase 2

Terminated

Conditions: Lupus Nephritis

Interventions: Drug: Placebo (Normal Saline)
Drug: Daxdilimab

First Posted Date: 2022-09-15

Last Posted Date: 2025-03-24

Lead Sponsor: Amgen

Target Recruit Count: 19

Registration Number: NCT05540665

Locations: 🇦🇷
Clinica Mayo de U.M.C.B. S.R.L, San Miguel De Tucumán, Argentina
🇧🇷
SER - Serviços Especializados em Reumatologia da Bahia S/S - ME, Salvador, Bahia, Brazil
🇧🇷
Irmandade Da Santa Casa de Misericordia de Porto Alegre, Porto Alegre, Rio Grande Do Sul, Brazil

and more 48 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy